Skip to main content
Premium Trial:

Request an Annual Quote

Emory University Purchases Corning Epic System for Drug Studies

NEW YORK (GenomeWeb News) — Emory University has added one of Corning’s label-free screening systems for use in its drug discovery research programs, the company said yesterday.
 
The university bought the Epic System for use in its Emory Chemical Biology Discovery Center, which is part of the National Institutes of Health-funded Molecular Libraries Screening Centers Network. The MLSCN includes ten screening centers that work to develop new chemical probes for drug research.
 
The Epic System is able to conduct biochemical and cell-based assays without radioactive or fluorescent dyes that could interfere with chemical reactions, said Corning.
 
Ron Verkleeren, who is business director for the Epic System, said in a statement that the instrument’s ability to monitor real-time responses of small molecular compounds in living cells will help streamline the university’s search for new drugs.
 

Financial terms of the agreement were not released.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.